Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258566 | 1.00 | SLC6A4 (0.79) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27810305 | 0.91 | SLC6A4 (0.74) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4258563 | 0.91 | SLC6A4 (0.74) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13964361 | 0.91 | SLC6A4 (0.78) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16220938 | 0.91 | SLC6A4 (0.77) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL178609 | 0.88 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL5569574 | 0.88 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL341698 | 0.88 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL33983 | 0.88 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28706942 | 0.88 | SLC6A4 (0.77) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138174-B2 | Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-03-20 | — | — | US | disclosed |
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2008-09-04 | — | — | US | disclosed |
| WO-2008084057-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214559-A1 | COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION | CNR1, OPRL1, CNR2 | SLC6A4 20/4885CYP1A2 190/4885CYP3A4 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.